Synovial sarcoma: From genetics to genetic-based animal modeling

Malay Haldar, R Randall, Mario R. Capecchi

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Synovial sarcomas are highly aggressive mesenchymal cancers that show modest response to conventional cytotoxic chemotherapy, suggesting a definite need for improved biotargeted agents. Progress has been hampered by the lack of insight into pathogenesis of this deadly disease. The presence of a specific diagnostic t(X;18) translocation leading to expression of the unique SYT-SSX fusion protein in effectively all cases of synovial sarcoma suggests a role in the etiology. Other nonspecific anomalies such as overexpression of Bcl-2, HER-2/neu, and EGFR have been reported, but their role in the pathogenesis remains unclear. Using gene targeting, we recently generated mice conditionally expressing the human SYT-SSX2 fusion gene from mouse endogenous ROSA26 promoter in chosen tissue types in the presence of Cre recombinase. These mice develop synovial sarcoma when SYT-SSX2 is expressed within myoblasts, thereby identifying a source of this enigmatic tumor and establishing a mouse model of this disease that recapitulates the clinical, histologic, immunohistochemical, and transcriptional profile of human synovial sarcomas. We review the genetics of synovial sarcoma and discuss the usefulness of genetics-based mouse models as a valuable research tool in the hunt for key molecular determinants of this lethal disease as well as a preclinical platform for designing and evaluating novel treatment strategies.

Original languageEnglish (US)
Pages (from-to)2156-2167
Number of pages12
JournalClinical Orthopaedics and Related Research
Volume466
Issue number9
DOIs
StatePublished - Sep 1 2008
Externally publishedYes

Fingerprint

Synovial Sarcoma
Gene Targeting
Myoblasts
Gene Fusion
Neoplasms
Drug Therapy
Research
SYT-SSX fusion protein

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Synovial sarcoma : From genetics to genetic-based animal modeling. / Haldar, Malay; Randall, R; Capecchi, Mario R.

In: Clinical Orthopaedics and Related Research, Vol. 466, No. 9, 01.09.2008, p. 2156-2167.

Research output: Contribution to journalArticle

Haldar, Malay ; Randall, R ; Capecchi, Mario R. / Synovial sarcoma : From genetics to genetic-based animal modeling. In: Clinical Orthopaedics and Related Research. 2008 ; Vol. 466, No. 9. pp. 2156-2167.
@article{c8c7f09315d7420ba9563c45d217c928,
title = "Synovial sarcoma: From genetics to genetic-based animal modeling",
abstract = "Synovial sarcomas are highly aggressive mesenchymal cancers that show modest response to conventional cytotoxic chemotherapy, suggesting a definite need for improved biotargeted agents. Progress has been hampered by the lack of insight into pathogenesis of this deadly disease. The presence of a specific diagnostic t(X;18) translocation leading to expression of the unique SYT-SSX fusion protein in effectively all cases of synovial sarcoma suggests a role in the etiology. Other nonspecific anomalies such as overexpression of Bcl-2, HER-2/neu, and EGFR have been reported, but their role in the pathogenesis remains unclear. Using gene targeting, we recently generated mice conditionally expressing the human SYT-SSX2 fusion gene from mouse endogenous ROSA26 promoter in chosen tissue types in the presence of Cre recombinase. These mice develop synovial sarcoma when SYT-SSX2 is expressed within myoblasts, thereby identifying a source of this enigmatic tumor and establishing a mouse model of this disease that recapitulates the clinical, histologic, immunohistochemical, and transcriptional profile of human synovial sarcomas. We review the genetics of synovial sarcoma and discuss the usefulness of genetics-based mouse models as a valuable research tool in the hunt for key molecular determinants of this lethal disease as well as a preclinical platform for designing and evaluating novel treatment strategies.",
author = "Malay Haldar and R Randall and Capecchi, {Mario R.}",
year = "2008",
month = "9",
day = "1",
doi = "10.1007/s11999-008-0340-2",
language = "English (US)",
volume = "466",
pages = "2156--2167",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Synovial sarcoma

T2 - From genetics to genetic-based animal modeling

AU - Haldar, Malay

AU - Randall, R

AU - Capecchi, Mario R.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Synovial sarcomas are highly aggressive mesenchymal cancers that show modest response to conventional cytotoxic chemotherapy, suggesting a definite need for improved biotargeted agents. Progress has been hampered by the lack of insight into pathogenesis of this deadly disease. The presence of a specific diagnostic t(X;18) translocation leading to expression of the unique SYT-SSX fusion protein in effectively all cases of synovial sarcoma suggests a role in the etiology. Other nonspecific anomalies such as overexpression of Bcl-2, HER-2/neu, and EGFR have been reported, but their role in the pathogenesis remains unclear. Using gene targeting, we recently generated mice conditionally expressing the human SYT-SSX2 fusion gene from mouse endogenous ROSA26 promoter in chosen tissue types in the presence of Cre recombinase. These mice develop synovial sarcoma when SYT-SSX2 is expressed within myoblasts, thereby identifying a source of this enigmatic tumor and establishing a mouse model of this disease that recapitulates the clinical, histologic, immunohistochemical, and transcriptional profile of human synovial sarcomas. We review the genetics of synovial sarcoma and discuss the usefulness of genetics-based mouse models as a valuable research tool in the hunt for key molecular determinants of this lethal disease as well as a preclinical platform for designing and evaluating novel treatment strategies.

AB - Synovial sarcomas are highly aggressive mesenchymal cancers that show modest response to conventional cytotoxic chemotherapy, suggesting a definite need for improved biotargeted agents. Progress has been hampered by the lack of insight into pathogenesis of this deadly disease. The presence of a specific diagnostic t(X;18) translocation leading to expression of the unique SYT-SSX fusion protein in effectively all cases of synovial sarcoma suggests a role in the etiology. Other nonspecific anomalies such as overexpression of Bcl-2, HER-2/neu, and EGFR have been reported, but their role in the pathogenesis remains unclear. Using gene targeting, we recently generated mice conditionally expressing the human SYT-SSX2 fusion gene from mouse endogenous ROSA26 promoter in chosen tissue types in the presence of Cre recombinase. These mice develop synovial sarcoma when SYT-SSX2 is expressed within myoblasts, thereby identifying a source of this enigmatic tumor and establishing a mouse model of this disease that recapitulates the clinical, histologic, immunohistochemical, and transcriptional profile of human synovial sarcomas. We review the genetics of synovial sarcoma and discuss the usefulness of genetics-based mouse models as a valuable research tool in the hunt for key molecular determinants of this lethal disease as well as a preclinical platform for designing and evaluating novel treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=50649097473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649097473&partnerID=8YFLogxK

U2 - 10.1007/s11999-008-0340-2

DO - 10.1007/s11999-008-0340-2

M3 - Article

C2 - 18563504

AN - SCOPUS:50649097473

VL - 466

SP - 2156

EP - 2167

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 9

ER -